Shares of BridgeBio (BBIO) Pharma are down $2.17, or 3%, to $68.55, but have come off session lows as traders discuss the company reportedly having cancelled out of the UBS biotech summit conference, trading contacts tell The Fly.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: